Advertisement
Screener

Vivos Therapeutics, Inc. (VVOS) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised

2.8 / 5 stars · 68/120 Roast Me

Vivos Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised

Vivos Therapeutics, Inc. (VVOS) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised of 1.98 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised · last filed 2026-08-14

  • Vivos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for the quarter ending 2026-06-30 was 0.00 shares.
  • Vivos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for the quarter ending 2026-03-31 was 1.98M shares.
  • Vivos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
  • Vivos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for the quarter ending 2024-12-31 was 345.00K shares.
  • Vivos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for fiscal 2025 was 180.00K shares, a 89.65% decline from fiscal 2024.
  • Vivos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for fiscal 2024 was 1.74M shares, a 178.69% increase from fiscal 2023.
  • Vivos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for fiscal 2023 was 624.00K shares.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 12 month
2026-06-300.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14
1.98M shares
10-Q · filed 2026-08-14
1.98M shares
derived: sum of 3 quarters · filed 2026-08-14
2026-03-311.98M shares
10-Q · filed 2026-05-20
1.98M shares
derived: sum of 2 quarters · filed 2026-05-20
2025-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15
180.00K shares
10-K · filed 2026-04-15
2025-09-30180.00K shares
10-Q · filed 2025-11-19
2024-12-31345.00K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15
345.00K shares
derived: sum of 2 quarters · filed 2026-04-15
345.00K shares
derived: sum of 3 quarters · filed 2026-04-15
1.74M shares
10-K · filed 2026-04-15
2024-09-300.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14
0.00 shares
derived: sum of 2 quarters · filed 2024-11-14
1.39M shares
10-Q · filed 2024-11-14
2024-06-300.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14
1.39M shares
10-Q · filed 2024-08-14
2024-03-311.39M shares
10-Q · filed 2024-05-14
2023-12-31624.00K shares
10-K · filed 2025-03-31

Similar stocks

Stock NameCountryMarket CapPE Ratio
Beyond Air, Inc. (XAIR)United States$0.003B-0.01
NEXGEL, INC. (NXGL)United States$0.002B
INVO Fertility, Inc. (IVF)United States$0.002B-0.71
Catheter Precision, Inc. (VTAK)United States$0.002B-0.23
Tenon Medical, Inc. (TNON)United States$0.002B
Autonomix Medical, Inc. (AMIX)United States$0.004B
Adagio Medical Holdings, Inc. (ADGM)United States$0.004B
Profusa, Inc. (PFSA)United States$0.002B
OSR Health, Inc. (OSRH)United States$0.004B-0.75
Bluejay Diagnostics, Inc. (BJDX)United States$0.004B